Satsuma Pharmaceuticals (stock symbol: STSA) Logo in transparent PNG and SVG formats

Satsuma Pharmaceuticals Logo large

Satsuma Pharmaceuticals Logo icon format

Satsuma Pharmaceuticals Logo large for dark backgrounds

Satsuma Pharmaceuticals Logo icon format for dark backgrounds

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

  • Website domain: satsumarx.com
  • Employees: 25
  • Marketcap: $33.45 Million USD

Page last updated on:

August 29th, 2022

Categories: